Peptides

5-Amino-1MQ

Evidence: animal_plus_anecdotal

Mechanism of Action

5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide, generating 1-methylnicotinamide (1-MNA). By inhibiting NNMT, 5-Amino-1MQ increases intracellular NAD+ levels, reduces 1-MNA production, suppresses lipogenesis in adipocytes, and modulates the methionine-homocysteine cycle. In vivo, it significantly reduces body weight, white adipose mass, and adipocyte size through enhanced energy expenditure and altered lipid metabolism.

Dosing Protocol

Standard: Research indicates 50-150 mg daily via oral administration, typically divided into 1-2 doses.

Maintenance: Research indicates 50 mg daily for maintenance metabolic optimization.

Administration: oralsubcutaneous

Timing: Morning dosing preferred. Can be taken with or without food.

Duration: 8-12 week cycles.

Notes

5-Amino-1MQ is technically a small molecule rather than a peptide, but is included in peptide optimization protocols for metabolic enhancement. The 5-Amino-1MQ + MOTS-c fat loss stack addresses two complementary metabolic pathways: NNMT inhibition (NAD+ preservation, reduced lipogenesis) and AMPK activation (enhanced energy expenditure). NNMT is overexpressed in adipose tissue of obese individuals, making it a compelling therapeutic target. Oral bioavailability is a significant advantage over injectable peptides. Still in preclinical phase — no human clinical trials published.

Stacking

  • MOTS-c
  • AOD-9604
  • Tesofensine
  • Semaglutide

Interactions

  • NAD+ precursors (NMN, NR) [LOW] — Synergistic — 5-Amino-1MQ preserves NAD+ while NMN/NR provides substrate for NAD+ synthesis.
  • MOTS-c [LOW] — Complementary mechanisms — the 5-Amino-1MQ + MOTS-c fat loss stack targets NNMT and AMPK pathways respectively.
  • Metformin [LOW] — Both modulate metabolic pathways; potentially synergistic for insulin sensitization.

Contraindications

  • Pregnancy and breastfeeding
  • Severe hepatic impairment
  • Active cancer (NAD+ modulation concern)

Side Effects

  • Mild GI discomfort
  • Headache
  • Diarrhea (uncommon)
  • Nausea at higher doses

Key Papers

  • 10.1016/j.bcp.2018.02.007
  • 10.1016/j.bcp.2019.02.008

Source Quality

Compounding pharmacy or research-grade supplier. Oral capsule form. Verify NNMT inhibition potency on COA.

Disclaimer: This information is for educational purposes only and is not medical advice. BioAccelera Labs does not diagnose, treat, or prescribe. Consult a licensed healthcare provider before using any compound.

Should 5-Amino-1MQ Be in Your Stack?

Take the free assessment and get personalized recommendations based on your biology and goals.

Get Your Free Protocolor take the assessment →
← Browse All 231 Compounds